Blood-derived biomaterials and platelet growth factors in regenerative medicine

Blood Reviews

Volumn 27, Issue 2, 2013, Pages 77-89

  Burnouf, Thierry ^a   Goubran, Hadi Alphonse ^b   Chen, Tim Mo ^c   Ou, Keng Liang ^a   El Ekiaby, Magdy ^d   Radosevic, Mirjana ^e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d Shabrawishi Hospital   (Egypt)

^e HUMAN PROTEIN PROCESS SCIENCES   (France)

Author keywords

Biomaterials; Fibrin; Growth factors; Platelet; Regeneration; Wound healing

Indexed keywords

BECAPLERMIN; BIOMATERIAL; BLOOD BIOMATERIAL; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBRIN GLUE; FIBRINOGEN; FIBRONECTIN; NEUTRALIZING ANTIBODY; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET GEL; PLATELET LYSATE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; TRANEXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTERIOR CRUCIATE LIGAMENT INJURY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BIODEGRADABILITY; BLOOD; BLOOD CLOTTING; BONE GRAFT; BURN; CARCINOGENICITY; CHONDROPATHY; CRYOPRECIPITATION; DECUBITUS; DIABETIC FOOT; EDENTULOUSNESS; HEMOSTASIS; HUMAN; KNEE OSTEOARTHRITIS; MUSCULOSKELETAL INJURY; NONHUMAN; ORTHOPEDIC SURGERY; PLASTIC SURGERY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; SIDE EFFECT; SKIN ULCER; SPORTS MEDICINE; STEM CELL EXPANSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING; TISSUE REGENERATION; TOOTH IMPLANT; VIRUS INFECTION; VIRUS TRANSMISSION; WOUND CARE; WOUND HEALING;

ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLATELET-RICH PLASMA; REGENERATIVE MEDICINE;

EID: 84875265895     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.02.001     Document Type: Article

References (211)

1. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007, 21:101-117.
2. Nurden A.T., Nurden P., Sanchez M., Andia I., Anitua E. Platelets and wound healing. Front Biosci 2008, 13:3532-3548.
3. Dahlback B. Blood coagulation. Lancet 2000, 355:1627-1632.
4. Furie B., Furie B.C. Molecular and cellular biology of blood coagulation. N Engl J Med 1992, 326:800-806.
5. Mann K.G., Lorand L. Introduction: blood coagulation. Methods Enzymol 1993, 222:1-10.
6. Davie E.W. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995, 74:1-6.
7. Schenone M., Furie B.C., Furie B. The blood coagulation cascade. Curr Opin Hematol 2004, 11:272-277.
8. van Rijn J.L., Govers-Riemslag J.W., Zwaal R.F., Rosing J. Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry 1984, 23:4557-4564.
9. Mann K.G., Butenas S., Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003, 23:17-25.
10. Spronk H.M., Govers-Riemslag J.W., ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003, 25:1220-1228.
11. Gailani D., Broze G.J. Factor XI activation in a revised model of blood coagulation. Science 1991, 253:909-912.
12. Furie B., Furie B.C. Molecular and cellular biology of blood coagulation. N Engl J Med 1992, 326:800-806.
13. Barrientos S., Stojadinovic O., Golinko M.S., Brem H., Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16:585-601.
14. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
15. Jackson S.P. The growing complexity of platelet aggregation. Blood 2007, 109:5087-5095.
16. Kapoor J.R. Platelet activation and atherothrombosis. N Engl J Med 2008, 358:1638. [author reply -9].
17. Schwertz H., Tolley N.D., Foulks J.M., Denis M.M., Risenmay B.W., Buerke M., et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006, 203:2433-2440.
18. Morel O., Toti F., Hugel B., Bakouboula B., Camoin-Jau L., Dignat-George F., et al. Procoagulant microparticles: disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol 2006, 26:2594-2604.
19. Piersma S.R., Broxterman H.J., Kapci M., de Haas R.R., Hoekman K., Verheul H.M., et al. Proteomics of the TRAP-induced platelet releasate. J Proteomics 2009, 72:91-109.
20. Macaulay I.C., Carr P., Gusnanto A., Ouwehand W.H., Fitzgerald D., Watkins N.A. Platelet genomics and proteomics in human health and disease. J Clin Invest 2005, 115:3370-3377.
21. Reed G.L. Platelet secretory mechanisms. Semin Thromb Hemost 2004, 30:441-450.
22. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312.
23. Graham S., Leonidou A., Lester M., Heliotis M., Mantalaris A., Tsiridis E. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. Expert Opin Investig Drugs 2009, 18:1633-1654.
24. Ruiz de Almodovar C., Lambrechts D., Mazzone M., Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009, 89:607-648.
25. Mackenzie F., Ruhrberg C. Diverse roles for VEGF-A in the nervous system. Development 2012, 139:1371-1380.
26. Kempen D.H., Creemers L.B., Alblas J., Lu L., Verbout A.J., Yaszemski M.J., et al. Growth factor interactions in bone regeneration. Tissue Eng Part B Rev 2010, 16:551-566.
27. Kim I., Mogford J.E., Chao J.D., Mustoe T.A. Wound epithelialization deficits in the transforming growth factor-alpha knockout mouse. Wound Repair Regen 2001, 9:386-390.
28. Brown G.L., Curtsinger L.J., White M., Mitchell R.O., Pietsch J., Nordquist R., et al. Acceleration of tensile strength of incisions treated with EGF and TGF-beta. Ann Surg 1988, 208:788-794.
29. Yamamoto H., Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J Neurosci 1990, 10:3469-3478.
30. Gray K., Ellis V. Activation of pro-BDNF by the pericellular serine protease plasmin. FEBS Lett 2008, 582:907-910.
31. Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306:487-491.
32. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982, 1:549-553.
33. Zacchigna S., Lambrechts D., Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008, 9:169-181.
34. Greenberg M.E., Xu B., Lu B., Hempstead B.L. New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 2009, 29:12764-12767.
35. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011, 10:209-219.
36. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007, 81:294-330.
37. Fumagalli F., Molteni R., Calabrese F., Maj P.F., Racagni G., Riva M.A. Neurotrophic factors in neurodegenerative disorders: potential for therapy. CNS Drugs 2008, 22:1005-1019.
38. Tapia-Arancibia L., Aliaga E., Silhol M., Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008, 59:201-220.
39. Fujimura H., Altar C.A., Chen R., Nakamura T., Nakahashi T., Kambayashi J., et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002, 87:728-734.
40. Nakahashi T., Fujimura H., Altar C.A., Li J., Kambayashi J., Tandon N.N., et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000, 470:113-117.
41. Lommatzsch M., Niewerth A., Klotz J., Schulte-Herbruggen O., Zingler C., Schuff-Werner P., et al. Platelet and plasma BDNF in lower respiratory tract infections of the adult. Respir Med 2007, 101:1493-1499.
42. Janmey P.A., Winer J.P., Weisel J.W. Fibrin gels and their clinical and bioengineering applications. J R Soc Interface 2009, 6:1-10.
43. Wolberg A.S. Determinants of fibrin formation, structure, and function. Curr Opin Hematol 2012, 19:349-356.
44. Weijers EM. Fibrin matrices for tissue engineering, naturally occurring fibrinogen variants alter cellular characteristics. [PhD]. Amsterdam: VU University Amsterdam; 2011.
45. Kaijzel E.L., Koolwijk P., van Erck M.G., van Hinsbergh V.W., de Maat M.P. Molecular weight fibrinogen variants determine angiogenesis rate in a fibrin matrix in vitro and in vivo. J Thromb Haemost 2006, 4:1975-1981.
46. Sell SA, Wolfe PS, Garg K, Mc Coll JM, Rodriguez IA, Bowlin GL. The Use of Natural Polymers in Tissue Engineering: A Focus on Electrospun Extracellular Matrix Analogues. Polymers 2010;2:522-53.
47. Almany L., Seliktar D. Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures. Biomaterials 2005, 26:2467-2477.
48. Dhandayuthapani B., Yoshida Y., Maekawa T., Kumar D.S. Polymeric scaffolds in tissue engineering application: a review. Int J Polym Sci 2011, 19. [Article ID 290602]. 10.1155/2011/290602.
49. Liu J., Xu H.H., Zhou H., Weir M.D., Chen Q., Trotman C.A. Human umbilical cord stem cell encapsulation in novel macroporous and injectable fibrin for muscle tissue engineering. Acta Biomater 2013, 9:4688-4697.
50. Lopez-Heredia M.A., Pattipeilohy J., Hsu S., Grykien M., van der Weijden B., Leeuwenburgh S.C., et al. Bulk physicochemical, interconnectivity, and mechanical properties of calcium phosphate cements-fibrin glue composites for bone substitute applications. J Biomed Mater Res A 2013, 101:478-490.
51. Pankov R., Yamada K.M. Fibronectin at a glance. J Cell Sci 2002, 115:3861-3863.
52. Labat-Robert J. Cell-Matrix interactions, the role of fibronectin and integrins. A survey. Pathol Biol (Paris) 2012, 60:15-19.
53. Lockhart M., Wirrig E., Phelps A., Wessels A. Extracellular matrix and heart development. Birth Defects Res A Clin Mol Teratol 2011, 91:535-550.
54. Wilson C.J., Clegg R.E., Leavesley D.I., Pearcy M.J. Mediation of biomaterial-cell interactions by adsorbed proteins: a review. Tissue Eng 2005, 11:1-18.
55. Gorbahn M., Klein M.O., Lehnert M., Ziebart T., Brullmann D., Koper I., et al. Promotion of osteogenic cell response using quasicovalent immobilized fibronectin on titanium surfaces: introduction of a novel biomimetic layer system. J Oral Maxillofac Surg 2012, 70:1827-1834.
56. Shin H., Jo S., Mikos A.G. Biomimetic materials for tissue engineering. Biomaterials 2003, 24:4353-4364.
57. Sarkar S., Schmitz-Rixen T., Hamilton G., Seifalian A.M. Achieving the ideal properties for vascular bypass grafts using a tissue engineered approach: a review. Med Biol Eng Comput 2007, 45:327-336.
58. Phillips J.B., King V.R., Ward Z., Porter R.A., Priestley J.V., Brown R.A. Fluid shear in viscous fibronectin gels allows aggregation of fibrous materials for CNS tissue engineering. Biomaterials 2004, 25:2769-2779.
59. Nectow A.R., Marra K.G., Kaplan D.L. Biomaterials for the development of peripheral nerve guidance conduits. Tissue Eng Part B Rev 2012, 18:40-50.
60. Nishida T. The role of fibronectin in corneal wound healing explored by a physician-scientist. Jpn J Ophthalmol 2012, 56:417-431.
61. Branford O.A., Brown R.A., McGrouther D.A., Grobbelaar A.O., Mudera V. Shear-aggregated fibronectin with anti-adhesive properties. J Tissue Eng Regen Med 2011, 5:20-31.
62. Mazzucco L., Balbo V., Cattana E., Guaschino R., Borzini P. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang 2009, 97:110-118.
63. Radosevich M., Goubran H.A., Burnouf T. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997, 72:133-143.
64. Burnouf T., Su C.Y., Radosevich M., Goubran H.A., El-Ekiaby M. Blood-derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. ISBT Sci Ser 2009, 4:136-142.
65. Everts P.A., Knape J.T., Weibrich G., Schonberger J.P., Hoffmann J., Overdevest E.P., et al. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol 2006, 38:174-187.
66. Borzini P., Mazzucco L. Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point?. ISBT Sci Ser 2007, 2:272-281.
67. Marx R.E. Platelet-rich plasma (PRP): what is PRP and what is not PRP?. Implant Dent 2001, 10:225-228.
68. Spotnitz W.D., Prabhu R. Fibrin sealant tissue adhesive-review and update. J Long Term Eff Med Implants 2005, 15:245-270.
69. Matras H. Fibrin seal: the state of the art. J Oral Maxillofac Surg 1985, 43:605-611.
70. Marx G. Evolution of fibrin glue applicators. Transfus Med Rev 2003, 17:287-298.
71. Burnouf-Radosevich M., Burnouf T., Huart J.J. Biochemical and physical properties of a solvent-detergent-treated fibrin glue. Vox Sang 1990, 58:77-84.
72. Aizawa P., Winge S., Karlsson G. Large-scale preparation of thrombin from human plasma. Thromb Res 2008, 122:560-567.
73. Mintz P.D., Mayers L., Avery N., Flanagan H.L., Burks S.G., Spotnitz W.D. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center. Ann Clin Lab Sci 2001, 31:108-118.
74. Gammon R.R., Avery N., Mintz P.D. Fibrin sealant: an evaluation of methods of production and the role of the blood bank. J Long Term Eff Med Implants 1998, 8:103-116.
75. Gosselin R.C., Larkin E., Owings J.T., Coehlo P. CryoSeal system, a new device for generating cryoprecipitate from plasma. Clin Chem 1997, 43:1782-1783.
76. Jackson M.R., MacPhee M.J., Drohan W.N., Alving B.M. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis 1996, 7:737-746.
77. Buchta C., Dettke M., Funovics P.T., Hocker P., Knobl P., Macher M., et al. Fibrin sealant produced by the CryoSeal FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting. Vox Sang 2004, 86:257-262.
78. Rock G., Neurath D., Lu M., Alharbi A., Freedman M. The contribution of platelets in the production of cryoprecipitates for use in a fibrin glue. Vox Sang 2006, 91:252-255.
79. Pisciotto P.T., Anderson K.C., Goodnough L.T., Kurtz S.R., Lane T.A., Sayers M.H., et al. Current trends: evolving concepts in transfusion medicine. The need for standardization of cryoprecipitate-derived fibrin adhesive. Transfus Sci 1993, 14:291-294.
80. Rock G., Neurath D., Semple E., Harvey M., Freedman M. Preparation and characterization of human thrombin for use in a fibrin glue. Transfus Med 2007, 17:187-191.
81. Su C.Y., Kuo Y.P., Nieh H.L., Tseng Y.H., Burnouf T. Quantitative assessment of the kinetics of growth factors release from platelet gel. Transfusion 2008, 48:2414-2420.
82. Su C.Y., Chiang C.C., Lai W.F., Lin K.W., Burnouf T. Platelet-derived growth factor-AB and transforming growth factor-beta1 in platelet gels activated by single-donor human thrombin. Transfusion 2004, 44:945.
83. Kumar V., Madsen T., Zhu H., Semple E. Stability of human thrombin produced from 11ml of plasma using the thrombin processing device. J Extra Corpor Technol 2005, 37:390-395.
84. Greppi N., Mazzucco L., Galetti G., Bona F., Petrillo E., Smacchia C., et al. Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. Biologicals 2011, 39:73-80.
85. Choukroun J., Diss A., Simonpieri A., Girard M.O., Schoeffler C., Dohan S.L., et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:e56-e60.
86. O'Neill E.M., Zalewski W.M., Eaton L.J., Popovsky M.A., Pivacek L.E., Ragno G., et al. Autologous platelet-rich plasma isolated using the Haemonetics Cell Saver 5 and Haemonetics MCS+ for the preparation of platelet gel. Vox Sang 2001, 81:172-175.
87. Blair P., Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009, 23:177-189.
88. Weibrich G., Kleis W.K., Hafner G., Hitzler W.E. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg 2002, 30:97-102.
89. Snyder E.L., Calhoun B.C. Topical platelet growth factor therapy: of lotions and potions. Transfusion 2001, 41:1186-1189.
90. Appel T.R., Potzsch B., Muller J., von Lindern J.J., Berge S.J., Reich R.H. Comparison of three different preparations of platelet concentrates for growth factor enrichment. Clin Oral Implants Res 2002, 13:522-528.
91. Weibrich G., Kleis W.K., Hafner G. Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit versus PCCS PRP system. Int J Oral Maxillofac Implants 2002, 17:184-190.
92. Zimmermann R., Jakubietz R., Jakubietz M., Strasser E., Schlegel A., Wiltfang J., et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion 2001, 41:1217-1224.
93. Zimmermann R., Arnold D., Strasser E., Ringwald J., Schlegel A., Wiltfang J., et al. Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang 2003, 85:283-289.
94. Kuo Y.P., Lee Y.L., Tseng Y.H., Su C.H., Burnouf T., Su C.Y. Influence of ethanol on the release of growth factors in human blood-derived platelet gels. Biologicals 2010, 38:120-127.
95. Giannini G., Mauro V., Agostino T., Gianfranco B. Use of autologous fibrin-platelet glue and bone fragments in maxillofacial surgery. Transfus Apher Sci 2004, 30:139-144.
96. Dohan D.M., Choukroun J., Diss A., Dohan S.L., Dohan A.J., Mouhyi J., et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:e45-e50.
97. Dohan D.M., Choukroun J., Diss A., Dohan S.L., Dohan A.J., Mouhyi J., et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:e51-e55.
98. Dohan D.M., Choukroun J., Diss A., Dohan S.L., Dohan A.J., Mouhyi J., et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101:e37-e44.
99. Su C.Y., Kuo Y.P., Tseng Y.H., Su C.H., Burnouf T. In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108:56-61.
100. Burnouf T., Lee C.Y., Luo C.W., Kuo Y.P., Chou M.L., Wu Y.W., et al. Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. Biologicals 2012, 40:21-30.
101. Wadhwa M., Barrowcliffe T.W., Mire-Sluis A.R., Thorpe R. Factor VIII concentrates and the immune system-laboratory investigations. Blood Coagul Fibrinolysis 1995, 6(Suppl. 2):S65-S79.
102. Hodge G., Flower R., Han P. Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF-beta as an immunomodulatory component in plasma-derived factor VIII concentrate. Br J Haematol 1999, 106:784-791.
103. Burnouf T., Tseng Y.H., Kuo Y.P., Su C.Y. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. Transfusion 2008, 48:1090-1098.
104. Lacoste E., Martineau I., Gagnon G. Platelet concentrates: effects of calcium and thrombin on endothelial cell proliferation and growth factor release. J Periodontol 2003, 74:1498-1507.
105. Martineau I., Lacoste E., Gagnon G. Effects of calcium and thrombin on growth factor release from platelet concentrates: kinetics and regulation of endothelial cell proliferation. Biomaterials 2004, 25:4489-4502.
106. Kuo Y., Su C., Tseng Y., Burnouf T. Comparison of growth factors content in platelet concentrates activated using human or bovine thrombin. Vox Sang 2008, 95:235.
107. Mazzucco L., Balbo V., Cattana E., Borzini P. Platelet-rich plasma and platelet gel preparation using Plateltex. Vox Sang 2008, 94:202-208.
108. Jabs A.D., Wider T.M., Debellis J., Hugo N.E. The effect of fibrin glue on skin-grafts in infected sites. Plast Reconstr Surg 1992, 89:268-271.
109. Kinoshita Y., Udagawa H., Tsutsumi K., Ueno M., Nakamura T., Iizuka T., et al. Bacteriological study of autologous cryoprecipitate-derived fibrin glue as the operative sealant. Transfus Med 2005, 15:429-433.
110. Burnouf T., Chou M.L., Wu Y.W., Su C.Y., Lee L.W. Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria. Transfusion 2012.
111. Hantash B.M., Zhao L., Knowles J.A., Lorenz H.P. Adult and fetal wound healing. Front Biosci 2008, 13:51-61.
112. El-Sharkawy H., Kantarci A., Deady J., Hasturk H., Liu H., Alshahat M., et al. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol 2007, 78:661-669.
113. Lee Y.L., Lee L.W., Su C.Y., Hsiao G., Yang Y.Y., S.J.L, et al. Virally-inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model. Transfusion 2013, 53:138-146.
114. van Buul G.M., Koevoet W.L., Kops N., Bos P.K., Verhaar J.A., Weinans H., et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 2011, 39:2362-2370.
115. Bendinelli P., Matteucci E., Dogliotti G., Corsi M.M., Banfi G., Maroni P., et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF. J Cell Physiol 2010, 225:757-766.
116. Dragoo J.L., Braun H.J., Durham J.L., Ridley B.A., Odegaard J.I., Luong R., et al. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med 2012, 40:1274-1281.
117. Martinowitz U., Spotnitz W.D. Fibrin tissue adhesives. Thromb Haemost 1997, 78:661-666.
118. Spotnitz W.D. Commercial fibrin sealants in surgical care. Am J Surg 2001, 182:8S-14S.
119. Burnouf T., Radosevich M., Goubran H. Local hemostatic blood products in hemophilia care: fibrin sealant and platelet gel. Monograph, World Federation of Hemophilia 2008, 1-14. World Federation of Hemophilia, Montreal.
120. Ronfard V., Broly H., Mitchell V., Galizia J.P., Hochart D., Chambon E., et al. Use of human keratinocytes cultured on fibrin glue in the treatment of burn wounds. Burns 1991, 17:181-184.
121. Ronfard V., Rives J.M., Neveux Y., Carsin H., Barrandon Y. Long-term regeneration of human epidermis on third degree burns transplanted with autologous cultured epithelium grown on a fibrin matrix. Transplantation 2000, 70:1588-1598.
122. Kim M.K., Choi S.W., Kim S.R., Oh I.S., Won M.H. Autologous chondrocyte implantation in the knee using fibrin. Knee Surg Sports Traumatol Arthrosc 2010, 18:528-534.
123. Wysocka A., Mann K., Bursig H., Dec J., Gazdzik T.S. Chondrocyte suspension in fibrin glue. Cell Tissue Bank 2010, 11:209-215.
124. Whitman D.H., Berry R.L., Green D.M. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997, 55:1294-1299.
125. Oyama T., Nishimoto S., Tsugawa T., Shimizu F. Efficacy of platelet-rich plasma in alveolar bone grafting. J Oral Maxillofac Surg 2004, 62:555-558.
126. de Obarrio J.J., Arauz-Dutari J.I., Chamberlain T.M., Croston A. The use of autologous growth factors in periodontal surgical therapy: platelet gel biotechnology-case reports. Int J Periodontics Restorative Dent 2000, 20:486-497.
127. Anitua E., Andia I., Ardanza B., Nurden P., Nurden A.T. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004, 91:4-15.
128. Marx R.E., Carlson E.R., Eichstaedt R.M., Schimmele S.R., Strauss J.E., Georgeff K.R. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85:638-646.
129. Rabelo G.D., de Paula P.M., Rocha F.S., Jordao Silva C., Zanetta-Barbosa D. Retrospective study of bone grafting procedures before implant placement. Implant Dent 2010, 19:342-350.
130. Gentile P., Bottini D.J., Spallone D., Curcio B.C., Cervelli V. Application of platelet-rich plasma in maxillofacial surgery: clinical evaluation. J Craniofac Surg 2010, 21:900-904.
131. Mannai C. Early implant loading in severely resorbed maxilla using xenograft, autograft, and platelet-rich plasma in 97 patients. J Oral Maxillofac Surg 2006, 64:1420-1426.
132. Lee H.J., Choi B.H., Jung J.H., Zhu S.J., Lee S.H., Huh J.Y., et al. Maxillary sinus floor augmentation using autogenous bone grafts and platelet-enriched fibrin glue with simultaneous implant placement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103:329-333.
133. Lee H.J., Choi B.H., Jung J.H., Zhu S.J., Lee S.H., Huh J.Y., et al. Vertical alveolar ridge augmentation using autogenous bone grafts and platelet-enriched fibrin glue with simultaneous implant placement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 105:27-31.
134. Anitua E., Aguirre J.J., Algorta J., Ayerdi E., Cabezas A.I., Orive G., et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater 2008, 84:415-421.
135. Marx R.E. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004, 62:489-496.
136. Borzini P., Mazzucco L. Platelet gels and releasates. Curr Opin Hematol 2005, 12:473-479.
137. Senet P., Bon F.X., Benbunan M., Bussel A., Traineau R., Calvo F., et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg 2003, 38:1342-1348.
138. Roldan J.C., Jepsen S., Miller J., Freitag S., Rueger D.C., Acil Y., et al. Bone formation in the presence of platelet-rich plasma vs. bone morphogenetic protein-7. Bone 2004, 34:80-90.
139. Castro F.P. Role of activated growth factors in lumbar spinal fusions. J Spinal Disord Tech 2004, 17:380-384.
140. Carreon L.Y., Glassman S.D., Anekstein Y., Puno R.M. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Spine 2005, 30:E243-E246. [discussion E7].
141. Weiner B.K., Walker M. Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine (Phila Pa 1976) 2003, 28:1968-1970. [discussion 71].
142. Chen T.M., Tsai J.C., Burnouf T. Cranioplasty using osteoconductive scaffold and platelet glue. J Trauma 2008, 65:1321-1327.
143. Chen T.M., Tseng Y.S., Tsai J.C. Burnouf T 2013, Single-donor allogeneic platelet fibrin glue and osteoconductive scaffold in orbital floor fracture reconstruction, Ann Plast Surg. 10.1097/SAP.0b013e31823b6880.
144. Chen T.M., Tsai J.C., Burnouf T. A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers. Dermatol Surg 2010, 36:453-460.
145. Crovetti G., Martinelli G., Issi M., Barone M., Guizzardi M., Campanati B., et al. Platelet gel for healing cutaneous chronic wounds. Transfus Apher Sci 2004, 30:145-151.
146. Carter M.J., Fylling C.P., Parnell L.K. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty 2011, 11:e38.
147. Tzeng YS, Deng SC, Wang CH, Tsai JC, Chen TM, Burnouf T. Treatment of non-healing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a pilot study. BioMed Research International in press.
148. Napolitano M., Matera S., Bossio M., Crescibene A., Costabile E., Almolla J., et al. Autologous platelet gel for tissue regeneration in degenerative disorders of the knee. Blood Transfus 2012, 10:72-77.
149. Filardo G., Kon E., Pereira Ruiz M.T., Vaccaro F., Guitaldi R., Di Martino A., et al. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc 2012, 20:2082-2091.
150. Andia I., Sanchez M., Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther 2012, 12:7-22.
151. Sampson S., Reed M., Silvers H., Meng M., Mandelbaum B. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 2010, 89:961-969.
152. Sanchez M., Guadilla J., Fiz N., Andia I. Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. Rheumatology (Oxford) 2012, 51:144-150.
153. Spakova T., Rosocha J., Lacko M., Harvanova D., Gharaibeh A. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 2012, 91:411-417.
154. Chen W.H., Liu H.Y., Lo W.C., Wu S.C., Chi C.H., Chang H.Y., et al. Intervertebral disc regeneration in an ex vivo culture system using mesenchymal stem cells and platelet-rich plasma. Biomaterials 2009, 30:5523-5533.
155. Liu H.Y., Wu A.T., Tsai C.Y., Chou K.R., Zeng R., Wang M.F., et al. The balance between adipogenesis and osteogenesis in bone regeneration by platelet-rich plasma for age-related osteoporosis. Biomaterials 2011, 32:6773-6780.
156. Anitua E., Sanchez M., Orive G., Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007, 28:4551-4560.
157. Mazzocca A.D., McCarthy M.B., Chowaniec D.M., Dugdale E.M., Hansen D., Cote M.P., et al. The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. Am J Sports Med 2012, 40:1742-1749.
158. Cervellin M., de Girolamo L., Bait C., Denti M., Volpi P. Autologous platelet-rich plasma gel to reduce donor-site morbidity after patellar tendon graft harvesting for anterior cruciate ligament reconstruction: a randomized, controlled clinical study. Knee Surg Sports Traumatol Arthrosc 2012, 20:114-120.
159. Taylor D.W., Petrera M., Hendry M., Theodoropoulos J.S. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med 2011, 21:344-352.
160. Mannello F., Tonti G.A. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!. Stem Cells 2007, 25:1603-1609.
161. Le Blanc K., Samuelsson H., Lonnies L., Sundin M., Ringden O. Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation 2007, 84:1055-1059.
162. Mizuno N., Shiba H., Ozeki Y., Mouri Y., Niitani M., Inui T., et al. Human autologous serum obtained using a completely closed bag system as a substitute for foetal calf serum in human mesenchymal stem cell cultures. Cell Biol Int 2006, 30:521-524.
163. Kocaoemer A., Kern S., Kluter H., Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
164. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
165. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005, 205:228-236.
166. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
167. Salvade A., Della Mina P., Gaddi D., Gatto F., Villa A., Bigoni M., et al. Characterization of platelet lysate (PL)-cultured mesenchymal stromal cells (MSC) and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods 2010, 16:201-214.
168. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007, 40:785-791.
169. Kilian O., Flesch I., Wenisch S., Taborski B., Jork A., Schnettler R., et al. Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. Eur J Med Res 2004, 9:337-344.
170. Su C.Y., Kuo Y.P., Lin Y.C., Huang C.T., Tseng Y.H., Burnouf T. A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sang 2009, 97:119-128.
171. Shih D.T., Chen J.C., Chen W.Y., Kuo Y.P., Su C.Y., Burnouf T. Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate. Transfusion 2011, 51:770-778.
172. Burnouf T., Chang C.W., Kuo Y.P., Wu Y.W., Tseng Y.H., Su C.Y. A chromatographically purified human TGF-beta1 fraction from virally inactivated platelet lysates. Vox Sang 2011, 101:215-220.
173. Burnouf T., Kuo Y.P., Huang C.T., Tseng Y.H., Lin C.T., Su C.Y. A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets. Transfusion 2010, 50:1702-1711.
174. Burnouf T., Kuo Y.P., Blum D., Burnouf S., Su C.Y. Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor. Transfusion 2012, 52:1721-1728.
175. Burnouf T., Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000, 14:94-110.
176. WHO Recommendations for the production, quality control and regulation of plasma for fractionation http://www.who.int/bloodproducts2005.
177. Horowitz B., Prince A.M., Horowitz M.S., Watklevicz C. Viral safety of solvent-detergent treated blood products. Dev Biol Stand 1993, 81:147-161.
178. Hilfenhaus J., Weidmann E. Fibrin glue safety: inactivation of potential viral contaminants by pasteurization of the human plasma components. Arzneimittelforschung 1985, 35:1617-1619.
179. Burnouf T. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. Biologicals 1992, 20:91-100.
180. Burnouf T., Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003, 9:24-37.
181. Burnouf T., Radosevich M., Goubran H.A., Willkommen H. Place of nanofiltration for assuring viral safety of biologicals. Curr Nanosci 2005, 1:189-201.
182. CPMP Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (revised). CPMP/BWP/CPMP/5136/03 1996, European Agency for the Evaluation of Medicinal Products (EMEA), London, [http://www.emea.eu.int].
183. CPMP Note for guidance on plasma -derived medicinal products. CPMP/BWP/269/95 rev.4 http://www.emea.eu.int.
184. WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products [Geneva]. http://www.WHO.int/bloodproducts.
185. WHO Guidelines on good manufacturing practices for blood establishments. Annex 4. WHO Tech Rep Ser 2011, 961:148-214.
186. Banninger H., Hardegger T., Tobler A., Barth A., Schupbach P., Reinhart W., et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993, 85:528-532.
187. Clark J., Crean S., Reynolds M.W. Topical bovine thrombin and adverse events: a review of the literature. Curr Med Res Opin 2008, 24:2071-2087.
188. Brown P., Will R.G., Bradley R., Asher D.M., Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis 2001, 7:6-16.
189. Bishop P.D., Lewis K.B., Schultz J., Walker K.M. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin Thromb Hemost 2006, 32(Suppl. 1):86-97.
190. Ratner M. Recombinant thrombin approved. Nat Biotechnol 2008, 26:250.
191. Anderson C.D., Bowman L.J., Chapman W.C. Topical use of recombinant human thrombin for operative hemostasis. Expert Opin Biol Ther 2009, 9:133-137.
192. Ballard J.L., Weaver F.A., Singla N.K., Chapman W.C., Alexander W.A. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg 2010, 210:199-204.
193. Schlag M.G., Hopf R., Zifko U., Redl H. Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. Acta Neurochir (Wien) 2002, 144:63-69.
194. Schlag M.G., Hopf R., Redl H. Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. Neurosurgery 2000, 47:1463-1467.
195. Chalmers R.T., Darling Iii R.C., Wingard J.T., Chetter I., Cutler B., Kern J.A., et al. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg 2010, 97:1784-1789.
196. Schwartz K.A., Lu G., Trosko J.E., Chang C.C. Serum from outdated human platelet concentrates: an alternative supplement for tissue (fibroblast) culture media. Am J Hematol 1984, 17:23-27.
197. Knighton D.R., Ciresi K.F., Fiegel V.D., Austin L.L., Butler E.L. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986, 204:322-330.
198. Heinemann V., Jehn U. Growth factors. A new dimension in understanding oncogenesis. Klin Wochenschr 1985, 63:740-746.
199. Wieman T.J., Smiell J.M., Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998, 21:822-827.
200. Smiell J.M. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group. Am J Surg 1998, 176:68S-73S.
201. Wieman T.J. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg 1998, 176:74S-79S.
202. Perry B.H., Sampson A.R., Schwab B.H., Karim M.R., Smiell J.M. A meta-analytic approach to an integrated summary of efficacy: a case study of becaplermin gel. Control Clin Trials 2002, 23:389-408.
203. Calhoun C.C., Cardenes O., Ducksworth J., Le A.D. Off-label use of becaplermin gel (recombinant platelet-derived growth factor-BB) for treatment of mucosal defects after corticocancellous bone graft: report of 2 cases with review of the literature. J Oral Maxillofac Surg 2009, 67:2516-2520.
204. Jakubowicz D.M., Smith R.V. Use of becaplermin in the closure of pharyngocutaneous fistulas. Head Neck 2005, 27:433-438.
205. Papanas N., Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf 2010, 33:455-461.
206. Di Stefano J.F., Kirchner M., Dagenhardt K., Hagag N. Activation of cancer cell proteases and cytotoxicity by EGF and PDGF growth factors. Am J Med Sci 1990, 300:9-15.
207. George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol 2003, 532:141-151.
208. Ziyadeh N., Fife D., Walker A.M., Wilkinson G.S., Seeger J.D. A matched cohort study of the risk of cancer in users of becaplermin. Adv Skin Wound Care 2011, 24:31-39.
209. Solchaga L.A., Hee C.K., Roach S., Snel L.B. Safety of recombinant human platelet-derived growth factor-BB in Augment((R)) Bone Graft. J Tissue Eng 2012, 3. [2041731412442668].
210. Thorn J.J., Sorensen H., Weis-Fogh U., Andersen M. Autologous fibrin glue with growth factors in reconstructive maxillofacial surgery. Int J Oral Maxillofac Surg 2004, 33:95-100.
211. Weibrich G., Kleis W.K., Hafner G., Hitzler W.E., Wagner W. Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified Curasan kit, with preparations received from a local blood bank. Clin Oral Implants Res 2003, 14:357-362.